Compare AbCellera Biologics Inc (ABCL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs DexCom, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.22 (market cap $2.99B), while DexCom, Inc. trades at $89.2 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 11.3× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | DXCM | |
|---|---|---|
Market Cap | $2.99B | $33.79B |
Sector | Health | Health |
52-Week High | $9.76 | $89.53 |
52-Week Low | $2.78 | $54.84 |
Enterprise Value | $2.58B | $33.24B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
